Sulfones in Dermatology

1. ABE, M., SHIMIZU, A., YOKOYAMA, Y. et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. Clin. Exp. Dermatol., 2008, 33, p. 759–763.

2. AL-SAID, M. S., GHORAB, M. M., NISSAN, Y. M. Dapson heterocytic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties. Chem. Cent. J., 2012, 6, 64.

3. ANDERSON, R., GATNER, E. M., VAN RENSBURG, C. E. et al. In vitro and in vivo effects of dapson on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Anitmicrob. Agents Chemother., 1981, 19, p. 495–503.

4. BEUTNER, E., CHORZELSKI, T., WILSON, R. et al. IgA pemphigus foliaceus. J. Am. Acad. Dermatol., 1989, 20, p. 89–97.

5. BISSINGER, E. M., HEINKE, R., SPANNHOFF, A. et al. Acyl derivatives of p-aminosulfonamides and dapson as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg. Med. Chem., 2011, 29, p. 3717–3731.

6. BJARNASON, B., SKOGLUND, C., FLOSADOTTIR, E. Childhood pemphigus vulgaris treated with dapson: a case report. Pediatr. Dermatol., 1998, 15, p. 381–383.

7. BOOTH, S. A., MOODY, C. E., DAHL, M. V. et al. Dapson suppresses integrin-mediated neutrophil adherence function. J. Invest. Dermatol., 1992, 98, p. 135–140.

8. BOZEMAN, P. M., LEARN, D. B., THOMAS, E. L. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapson. Biochem. Pharmacol., 1992, 44, p. 553–563.

9. BURROWS, M., BHOGAL, B., BLACK, M. et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br. J. Dermatol., 1993, 128, p. 332–338.

10. CETKOVSKÁ, P., KOMOROUSOVÁ, M., LOMICOVÁ, I. Management of a pemphigus with IgA and IgG antibodies and coexistent lung cancer. Dermatol. Ther., 2014, 27, 4, p. 236–239.

11. CETKOVSKA, P., PIZINGER, K. Childhood pemphigus associated with montelukast administration. Clin. Exp. Dermatol., 2003, 28, 3, p. 328–329.

12. COHEN, D. M., BEN-AMITAI, D., FEINMESSER, M. et al. Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr. Dermatol., 2009, 26, p. 569–574.

13. COHEN, P. R. Neutrophilic dermatoses: a review of current treatment options. Am. J. Clin. Dermatol., 2009, 10, p. 301–312.

14. COLEMAN, M. D. Dapson-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology, 2001, 162, p. 53–60.

15. DE HAAS, E., DE WIT, R., VAN VOLTEN, W. Non-HIV-related Kaposi’s sarcoma suppressed by dapson. Br. J. Dermatol., 1996, 135, p. 813–814.

16. DIAZ-RUIZ, A., ZAVALA, C., MONTES, S. et al. Antioxidant, anti-inflammatory and antiapoptotic effects of dapson in a model of brain ischemia/reperfusion in rats. J. Neurosci. Res., 2008, 86, p. 3410–3419.

17. DRAYER, D. E., STRONG, J. M., JONES, B. et al. In vitro acetylation of drugs by human blood cells. Drug. Metab. Dispos., 1974, 2, p. 499–505.

18. EDMONDS, B., HODGE, J., RIETSCHEL, R. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr. Dermatol., 1991, 8, p. 296–299.

19. ERDI, H., ANADOLU, R., PISKIN, G. et al. Malignant pyoderma: a clinical variant of pyoderma gangrenosum. Int. J. Dermatol., 1996, 35, p. 811–813.

20. FOSTER, C., NEUMANN, R., TAUBER, J. Long term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc. Ophthalmol., 1992, 82, p. 223–229.

21. FRÄKI, J. E., HOPSU-HAVU, V. K. Inhibition of human skin proteinases by chloroquine, dapson and sulfapyridine. Arch. Dermatol. Res., 1977, 259, p. 113–115.

22. FRY, L. Dermatitis herpetiformis: problems, progress and prospects. Eur. J. Dermatol., 2002, 12, 6, p. 520–531.

23. FRY, L. Fine points in the management of dermatitis herpetiformis. Semin. Dermatol., 1988, 7, p. 206–211.

24. GHATE, J., JORIZZO, J. Behcet’s disease and complex aphthosis. J. Am. Acad. Dermatol., 1999, 40, p. 1–18.

25. GRABBE, J., HAAS, N., MÖLLER, A. et al. Erythema elevatum diutinum – evidence for disease-dependent leucocyte alterations and response to dapson. Br. J. Dermatol., 2000, 143, p. 415–420.

26. GÜRCAN, H. M., AHMED, A. R. Efficacy of dapson in the treatment of pemphigus and pemphigoid: analysis of current data. Am. J. Clin. Dermatol., 2009, 10, p. 383–396.

27. HAMADA, K., HIYOSHI, T., KOBAYASHI, S. et al. Anticonvulsive effect of dapson (4,4'-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Epilepsy Res., 1991, 10, p. 93–102.

28. HARGRAVE, D. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br. J. Neurosurg., 2009, 23, p. 351–363.

29. HASHIMOTO, K., SINGER, K., LAZARUS, G. The effect of corticosteroids, dapson and gold on plasminogen activator synthesis and secretion by human epidermal cells cultured with pemphigus antibody. Br. J. Dermatol., 1984, 110, p. 297.

30. HEGARTY, A. M., ORMOND, M., SWEENEY, M. et al. Dapson efficacy and adverse events in the management of mucous membrane pemphigoid. Eur. J. Dermatol., 2010, 20, p. 223–224.

31. HOMEIDA, M., BABIKR, A., DANESHMEND, T. K. Dapson-induced optic atrophy and motor neuropathy. Br. Med. J., 1980, 281, p. 1180.

32. HONEYMAN, J., HONEYMAN, A., LOBITZ, W. et al. The enigma of bullous pemphigoid and dermatitis herpetiformis. Arch. Dermatol., 1972, 106, p. 22–25.

33. HRUZA, G., FRIEDMAN-KIEN, A., LAUBENSTEIN, L. et al. Dapson for AIDS-associated Kaposi’s sarcoma [letter]. Lancet, 1985, 1, p. 642.

34. CHEN, X. Y., BUSCHMANN, H., BOLM, C. Sulfoximine- and sulfilimine-based DAPSON analogs: syntheses and bioactivities. Synlett, 2012, 23, p. 2808–2810.

35. ISHIDA, S., HAMADA, K., YAGI, K. et al. Comparing the anticonvulsive effects of dapson on amygdala-kindled seizures and hippocampal-kindled seizures in rats. Acta Neurol. Scand., 1992, 85, p. 132–135.

36. JACYK, W. Behcet’s disease in South African blacks: report of five cases. J. Am. Acad. Dermatol., 1994, 30, p. 869–873.

37. JEFFES, E., AHMED, A. Adjuvant therapy of bullous pemphigoid with dapson. Clin. Exp. Dermatol., 1989, 14, p. 132–136.

38. JEFFES, E. W., KAPLAN, R., AHMED, A. Acantholysis produced in vitro with pemphigus serum: hydrocortisone inhibits acantholysis, while dapson and 6-mercaptopurine do not inhibit acantholysis. J. Clin. Immunol., 1984, 4, p. 359–363.

39. KAMINSKY, C., KAMINSKY, A., SCHICCI, C. et al. Acne: Treatment with diaminodiphenylsulfone. Cutis, 1974, 13, p. 869–871.

40. KAR, B. R. Dapson-induced photosensitivity: a rare clinical presentation. Photodermatol. Photoimmunol. Photomed., 2008, 24, p. 270–271.

41. KASPERKIEWICZ, M., ZILLIKENS, D. The pathophysiology of bullous pemphigoid. Clin. Rev. Allergy Immunol., 2007, 33, p. 67–77.

42. KAST, R. E., LEFRANCE, F., KARPEL-MASSLER, G. et al. Why dapson stops seizures and may stop neutrophils’ delivery of VEGF to glioblastoma. Br. J. Neurosurg., 2012, 26, p. 813–817.

43. KAST, R. E., SCHEUERLE, A., WIRTZ, CR. et al. The rationale of targeting neutrophils with dapson during glioblastoma treatment. Anticancer Agents Med. Chem., 2011, 11, p. 756–761.

44. KATZ, S. I., HERTZ, K. C., CRAWFORD, P. S. et al. Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions. J. Invest. Dermatol., 1976, 67, p. 688–690.

45. KENNER, D. J., HOLT, K., AGNELLO, R. et al. Permanent retinal damage following massive dapson overdose. Br. J. Ophthalmol., 1980, 64, p. 741–744.

46. KHAN, F. D., ROYCHOWDHURY, S., NEMES, R. et al. Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapson in normal human keratinocytes. Toxicology, 2006, 218, p. 90–99.

47. KHAN, G. Dapson is safe during pregnancy. J. Am. Acad. Dermatol., 1985, 13, p. 838–839.

48. KNUDSON, R. M., KALAAJI, A. N., BRUCE, A. J. The management of mucous membrane pemphigoid and pemphigus. Dermatol. Ther., 2010, 23, p. 268–280.

49. KUMAR, B., GANGULY, N. K., KAUR, S. et al. Effect of dapson (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Lepr. India, 1983, 55, p. 465–471.

50. KUMAR, R. H., KUMAR, M. V., THAPPA, D. M. Dapson syndrome – a five year retrospective analysis. Indian J. Lepr., 1998, 70, p. 271–276.

51. LAMMERS, A. M., VAN DE KERKHOF, P. C., SCHALWIJK, J. et al. Elastase, a marker for neutrophils in skin infiltrates. Br. J. Dermatol., 1986, 115, p. 181–186.

52. LANG, P. G. Sulfones and sulfonamides in dermatology today. J. Am. Acad. Dermatol., 1979, 1, p. 479–492.

53. LEVER, W. Pemphigus and pemphigoid. Springfield: Charles C Thomas Publisher, 1965.

54. LORENZ, M., WOZEL, G., SCHMITT, J. Hypersensitivity reactions to dapson: a systematic review. Acta Derm. Venereol., 2012, 92, p. 194–199.

55. MANGELSDORF, H., WHITE, W., JORIZZO, J. Behcet’s disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J. Am. Acad. Dermatol., 1996, 34, p. 745–750.

56. MARTIN, J., ROENIGK, H. J., LYNCH, W. et al. Relapsing polychondritis treated with dapson. Arch. Dermatol., 1976, 112, p. 1272–1274.

57. MATTHEWS, C., SAIHAN, E., WARIN, R. Urticaria-like lesions associated with systemic lupus erythematosus: Response to dapson. Br. J. Dermatol., 1978, 99, p. 555.

58. MCIEJOWSKA, E., JABLONSKA, S., CHORZELSKI, T. Is pemphigus herpetiformis an entity? Int. J. Dermatol., 1987, 26, p. 571–577.

59. MEHRAVARAN, M., MORVAY, M., MOLNAR, K. et al. Juvenile pemphigus foliaceus. Br. J. Dermatol., 1998, 139, p. 496–499.

60. MOBINI, N., NAGARWALLA, N., AHMED, R. Oral pemphigoid. Subset of cicatricial pemphigoid. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 1998, 85, p. 37–43.

61. NICOLAS, MEO., KRAUSE, PR., GIBSON, LE. et al. Dermatitis herpetiformis – Review. Int. J. Dermatol., 2003, 42, p. 588–600.

62. NICHOLAS, M. K., LUKAS, R. V., CHMURA, S. et al. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin. Oncol., 2011, 38, p. 243–253.

63. NIIMI, Y., KAWANA, S., KUSUNOKI, T. IgA pemphigus: A case report and its characteristic clinical features compared with subcorneal pustular dermatosis. J. Am. Acad. Dermatol., 2000, 43, p. 546–549.

64. NISHINA, M., SAITO, E., KINOSHITA, M. Correction of severe leukopenia and thrombocytopenia in systemic lupus erythematosus by treatment with dapson. J. Rheumatol., 1997, 24, p. 811–812.

65. NIWA, Y., MIYACHI, Y. Inhibitor effects of dapson on enzymatic acitivities of membrane phospholipids in human blood cells. Arch. Dermatol. Res., 1985, 277, p. 473–477.

66. NIWA, Y., SAKANE, T., MIYACHI, Y. Dissociation of the inhibitory effect of dapson on the generation of oxygen intermediates – in comparison with that of colchicine and various scavengers. Biochem. Pharmacol., 1984, 33, p. 2355–2360.

67. NURNBERG, W., GRABBE, J., CZARNETZKI, B. Urticarial vasculitis syndrome effectively treated with dapson and pentoxifylline. Acta Derm. Venereol. (Stockh), 1995, 75, p. 54–56.

68. PARK, B. K., BOOBIS, A., CLARKE, S. et al. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov., 2011, 10, p. 292–306.

69. PERSON, J., ROGERS, RIII. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch. Dermatol., 1977, 113, p. 610–615.

70. PIETTE, E. W., WERTH, V. P. Dapson in the management of autoimmune bullous diseases. Dermatol. Clin., 2011, 29, p. 561–564.

71. POULSEN, A., HULTBERG, B., THOMSEN, K. et al. Regression of Kaposi’s sarcoma in AIDS after treatment with dapson [letter]. Lancet, 1984, 1, p. 560.

72. PRONEUF, M., DUTERQUE, M., SOTTO, A. et al. Unusual erythema elevatum diutinum with fibrohistiocytic proliferation. Br. J. Dermatol., 1996, 134, p. 1131–1134.

73. PRUSSICK, R., ALI, M. A., ROSENTHAL, D. et al. The protective effect of vitamin E on the hemolysis associated with dapson treatment in patients with dermatitis herpetiformis. Arch. Dermatol., 1992, 128, p. 210–213.

74. REUNALA, T. Dermatitis herpetiformis. Clinics in Dermatology, 2001, 19, p. 728–736.

75. RIOS, C., NADER-KAWACHI, J., RODRIGUEZ-PAYÁN, A. J. et al. Neuroprotective effect of dapson in an occlusive model of focal ischemia in rats. Brain Res., 2004, 999, p. 212–215.

76. RODRÍGUEZ, E., MÉNDEZ-ARMENTA, M., VILLEDA-HERNÁNDEZ, J. et al. Dapson prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology, 1999, 139, 111–118.

77. ROGERS, R. S., SEEHAFER, J., PERRY, H. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapson. J. Am. Acad. Dermatol., 1982, 6, p. 215–223.

78. ROSS, C. Treatment of acne vulgaris with dapson. Br. J. Dermatol., 1961, 73, p. 367–370.

79. RUZICKA, T., GOERZ, G. Dapson in the treatment of lupus erythematosus. Br. J. Dermatol., 1981, 104, p. 53–56.

80. RUZICKA, T., WASSERMAN, S. I., SOTER, N. A. et al. Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapson. J. Allergy Clin. Immunol., 1983, 72, p. 365–370.

81. SALAVEC, M. Autoimunitní subepidermální bulózní onemocnění – část II. Ostatní subepidermální puchýřnaté autoimunitní dermatózy – dermatitis herpetiformis, lineární IgA bulózní dermatóza, epidermolysis bullosa acquisita. Referátový výběr z dermatovenerologie, Speciál 1/2013, s. 35–47.

82. SANTAMARIA, A., ORDAZ-MORENO, J., RUBIO-OSORNIO, M. et al. Neuroprotective effect of dapson against quinolinate- and kainate-induced striatal neurotoxicities in rats. Pharmacol. Toxicol., 1997, 81, p. 271–275.

83. SCHADENDORF, D., HAAS, N., NURNBERGER, F. et al. Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapson therapy [letter]. Hautarzt, 1993, 44, p. 653–657.

84. SCHMIDT, E., REIMER, S., KRUSE, N. et al. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapson. Clin. Exp. Immunol., 2001, 124, p. 157–162.

85. SMITH, L. C., COX, N. H. Dapson treatment for eosinophilic fasciitis. Arch. Dermatol., 2008, 144, p. 845–847.

86. ČESKÁ DERMATOVENEROLOGICKÁ SPOLEČNOST, obor Dermatovenerologie. Standard pro dermatitis herpetiformis. Dostupné na www: http://www.lfhk.cuni.cz/dermat/indexcz.htm.

87. STÖCKEL, S., MEURER, M., WOZEL, G. Dapson-induced photodermatitis in a patient with linear IgA dermatosis. Eur. J. Dermatol., 2001, 11, p. 50–53.

88. THOMPSON, D. M., SOUHAMI, R. Suppression of the arthus reaction in the guinea-pig by dapson. Proc. R. Soc. Med., 1975, 68, p. 273.

89. THUONG-NGUYEN, V., KADUNCE, D. P., HENDRIX, J. D. et al. Inhibition of neutrophil adherence to antibody by dapson: a possible therapeutic mechanism of dapson in the treatment of IgA dermatoses. J. Invest. Dermatol., 1993, 100, p. 349–355.

90. UETRECHT, J., ZAHID, N., SHEAR, N. H. et al. Metabolism of dapson to a hydroxylamine by human neutrophils and mononuclear cells. J. Pharmacol. Exp. Ther., 1988, 245, p. 274–279.

91. VENNING, V., MILLARD, P., WOJNAROWSKA, F. Dapson as first line therapy for bullous pemphigoid. Br. J. Dermatol., 1989, 120, p. 83–92.

92. WALKER, J. G., KADIA, T., BROWN, L. et al. Dapson induced methemoglobinemia in a patient with glioblastoma. J. Neurooncol., 2009, 94, p. 149–152.

93. WALLACH, D. Intraepidermal IgA pustulosis. J. Am. Acad. Dermatol., 1992, 27, p. 993–1000.

94. WOLF, R., TÜZÜN, B., TÜZÜN, Y. Dapson: unapproved uses or indications. Clinics in Dermatology, 2000, 18, 1, p. 37–53.

95. WOLFF, K. Subcorneal pustular dermatosis is not pustular psoriasis. Am. J. Dermatopathol., 1981, 3, p. 381–382.

96. WOZEL, G. Dapson – Pharmakologie. Thieme, Stuttgart: Wirkmechanismus und klinischer Einsatz; 1996.

97. WOZEL, G., BLASUM, CH. Dapson in dermatology and beyond. Arch. Dermatol. Res., 2014, 306, 2, p. 103–124.

98. YASUDA, H., KOBAYASHI, H., HASHIMOTO, T. et al. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br. J. Dermatol., 2000, 143, p. 144–148.

99. YAZDANYAR, S., BOER, J., INGVARSSON, G. et al. Dapson therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology, 2011, 222, p. 342–346.

100. ZHU, K. J., HE, F.T., JIN, N. et al. Complete atrioventricular block associated with dapson therapy: a rare complication of dapson-induced hypersensitivity syndrome. J. Clin. Pharm. Ther., 2009, 34, p. 489–492.

101. ZHU, Y. L., STILLER, M. J. Dapson and sulfones in dermatology: overview and update.J. Am. Acad. Dermatol., 2001 Sep, 45, 3, p. 420–434.

102. ZONE, J. J., MEYER, L. J. Dermatitis herpetiformis. Immunol. Ser., 1989, 46, p. 565–582.